Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

FLOW Trial Results: GLPs, the Kidneys, and Even More to Come!!

Robert Busch

Insulin Treatment in Patients with Type 2 Diabetes: When to Use Comb…

Emory Diabetes Education Training Academy

G. Umpierrez

Medical Management of Diastolic Dysfunction: Does The Emperor Finall…

Top Ten Topics in Clinical Cardiology 2023

S. Pinney

Important Safety Information - Off-Target Effects of New Therapies f…

Ronald Goldenberg

Current Status of Prevention and Treatment of Diabetic Nephropathy

George Bakris

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

American Heart & Vascular Institute

M. Kittleson

Controlling Blood Pressure in the Patient with HFpEF

MUSC Cardiology

J. Basile

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

ACC 2024 Insights

M. Costanzo

A Pathophysiologic Approach for Treating Type 2 Diabetes: Part 2

Primary Care Education Consortium

E. Miller